To establish a productive infection in host cells, viruses often use one or multiple host 28 membrane glycoprotein as their receptors. For Influenza A virus (IAV) such a glycoprotein 29 receptor has not been described, to date. Here we show that IAV is using the host membrane 30 
influenza virus. While glycoprotein CD66c was found necessary for the uptake of influenza 117 virus by cells, it did not affect the entry of another non-IAV RNA virus (Hepatitis C virus) . 118
Finally, to confirm our hypothesis, we pre-incubated IAV particles with biologically active 119 human recombinant CD66c protein (expressed in mouse myeloma cell line) prior to infecting 120 BALB/c mice. Interestingly, we observed a significant decrease in infection and cytopathic 121 effects in mice lungs presumably due to masking of the NA spike protein with rCD66c protein.
122
This study on identification of CD66c as a receptor for the influenza A virus has 123 potential to further our knowledge on the mechanism of virus entry. Additionally, this 124 newfound receptor brings to attention a new target for anti-viral interventions. Since CD66c is 125 also an active immunomodulatory molecule (present on T cells, B cells and neutrophils) this 126 finding may lead to exploration of early immunomodulatory events associated with the 127 interaction between viral NA and CD66c. 128 129 author/funder. All rights reserved. No reuse allowed without permission.
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Results 130

Overexpression of CD66c on human lung cell surface resulted in increased virus binding 131
The physical interaction between influenza NA and CD66c of virus-infected cells was 132 confirmed earlier by co-immunoprecipitation assays (12) 
Cells overexpressing CD66c showed increased virus entry 151
We further sought to determine if CD66c overexpression in host cells increased virus entry. We 152 quantified mRNA levels of viral NP and M1 after harvesting PR8 infected A549 lung cells, 153 approximately 8 hours post-infection, h.p.i (one life cycle). Cells overexpressing CD66c 154 showed 6-8 fold increase in the levels of M1 and NP mRNA (Figure 2a, b) . We also measured 155 author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/104026 doi: bioRxiv preprint viral NP protein in CD66c expressing A549 cells that showed 7 fold increase in its expression 156 levels (Figure 2c-f) . To demonstrate that the NA-CD66c interaction affected virus entry in 157 other types of cells as well, we performed similar experiments using the mouse embryonic 158 fibroblast cell line NIH3T3. CD66c expressing NIH3T3 cells (NIH3T3-CD66c cells) showed 159 an increase in NP mRNA levels as against the NIH3T3 cells (Figure 3a) . Likewise we checked 160 the virus binding and entry in CD66c overexpressing Lec2CHO cell lines. Lec2CHO cell lines 161 transiently overexpressing CD66c favored virus binding on cell surface and subsequent uptake 162 of the virus into cells (Figure 3b, c) . HEK cells overexpressing CD66c cells showed an 163 increase in virus entry, which was monitored by increase in the NP mRNA levels (Figure 3d) . was not observed on the surface of cells silenced for CD66c, as observed by a reduced red 177 signal for neuraminidase (Lower two panels, Figure 4a ). In contrast, mock siRNA treated cells 178 showed significant endogenous expression levels of CD66c (green) both in viral infected (5') 179 and uninfected cells (UI). As expected, these cells upon infection showed significant viral 180 binding on the cell surface, which was probed by viral NA (red). Accordingly, these cells 181 author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/104026 doi: bioRxiv preprint 8 showed significant colocalization of NA (red) with CD66c (green) in merged fields (yellow) 182 (Figure 4a) . Altogether, we observed that cells with endogenous level of CD66c showed 183 significant virus binding at the cell surface however cells silenced for CD66c did not show any 184 visible virus binding on the cell surface due to absence of surface receptor CD66c (Figure 4a) . 185
To validate our immunofluorescence assay (IFA) data we performed a western blot analysis to 186 study the effect of siRNA-mediated-silencing of CD66c in virus entry (Figure 4b) The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/104026 doi: bioRxiv preprint this experiment, a monolayer of NIH3T3-CD66c cells when treated with mAb anti-CD66c at 208 increasing concentrations of 1.0µg/mL, 1.5µg/mL, 2.0µg/mL and 8.0µg/mL, preceding virus 209 infection. This experiment revealed significant decrease in virus infection in a dose dependent 210 manner. The virus entry levels in these cells were determined by the mRNA levels of viral NP 211 (Figure 5a ). Likewise inhibition of virus entry was observed by determining expression levels 212 of viral NP protein in NIH3T3-CD66c cells, when treated with increasing concentrations of 213 anti-CD66c mAb prior to infection (Figure 5b) . From these results, lower levels of NP (mRNA 214 and protein) in anti-CD66c mAb treated cells suggested that masking of CD66c on host cell 215 surface by mAb reduced its access to NA spike protein present on the envelope of the infecting 216 virus particles thus inhibiting virus binding and uptake. For conclusive validation of our 217 hypothesis, we finally performed mAb mediated receptor blockade experiment in A549 lung 218 cells with endogenous (not overexpressed) levels of CD66c on the cell surface. In a control 219 experiment we also tested the effect of mock antibody (IgG isotype) binding on the A549 cell 220 monolayer as against CD66c binding (Figure 6a, b) . We observed a corresponding decrease in 221 virus entry when cells were treated with mAb anti-CD66c at the respective concentrations of 222 1.0 µg/mL, 1.5µg/mL, 2.0µg/mL, 4.0µg/mL and 8.0 µg/mL (Figure 6c ). Inhibition of virus 223 entry was demonstrated by measuring a corresponding reduction in expression levels of viral 224 NP protein in infected cells by flow cytometry (Figure 6d-g ). The dose dependence of mAb 225 anti-CD66c in the inhibition of viral entry was also confirmed by quantitating another viral 226 protein, M1 in the corresponding cells (Figure 6h, i) . One set of the antibody mediated receptor 227 blockade experiment was also studied under confocal microscopy, which showed similar 228 inhibition of virus entry into A549 cells that were treated with 4.0 µg/mL of anti-CD66c mAb 229 (Figure 6j) (Figure 7a) . Also, the 244 (Figure 7c ) as compared to that of other two glycoproteins (EGFR and DC-SIGN) . 254
An increase in virus binding to receptor leads to consequent virus entry into cells. 255 Therefore, after virus binding experiments, we tested and compared ability of other two 256 glycoproteins (EGFR and DC-SIGN) in virus entry with that of CD66c, at the same 257 experimental conditions. We observed, CD66c overexpression in lung cells resulted significant 258 author/funder. All rights reserved. No reuse allowed without permission.
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In contrast, overexpression of DC-SIGN and EGFR did not show much change in virus entry, 260 except for a modest increase in viral NP (Figure 8b, 8c) . We also found that transient 261 overexpression of CD66c did not affect the expression levels of glycoproteins EGFR and DC-262 SIGN (Figure 8a) . Similarly, the overexpression of these two glycoproteins (DC-SIGN and 263 EGFR) had no effect on CD66c expression (Figure 8b, 8c) . 264
265
Absence of CD66c in cells showed no decrease in entry of non-IAV virus 266
The membrane glycoprotein DC-SIGN has been documented to serve as a low-specificity virus 267 receptor for IAV and is postulated to facilitate the entry of other viruses like HIV (Human 268 immunodeficiency virus) and HCV (Hepatitis C virus) (11). Critically, we argued that CD66c 269 being a membrane glycoprotein might also be expected to serve as a low-specificity receptor 270 for viruses other than IAV. To this effect, we sought to establish the specificity of CD66c 271 towards influenza virus against an unrelated RNA virus -HCV. We conducted these 272 experiments in human hepatoma Huh cells that were siRNA-mediated-silenced for CD66c 273 expression. We monitored HCV entry into these Huh cells by checking the expression levels of 274 the HCV NS3 protein (Figure 9 ). This data clearly showed that the absence of CD66c in Huh 275 cells had not inhibited entry of HCV, thus proving that CD66c was not a low-specificity 276 general viral receptor. 277
278
Influenza virus incubated with CD66c showed reduction in alveolitis 279
Since we had clearly shown that CD66c was capable of binding to the NA of IAV, we reasoned 280 if we could use heterologously expressed recombinant CD66c protein to bind IAV particles, 281 this should in principle bring down the infectivity of the virus in mice. Thus, we incubated 1µg 282 of biologically active recombinant CD66c (rCD66c), that was produced in mouse myeloma cell 283 lines, with 7.4 X 10 7 PFU IAV before intranasal infection of BALB/c mice. After ten days of 284 author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/104026 doi: bioRxiv preprint infecting mice with virus through intranasal inoculation, we noticed a considerable reduction in 285 alveolitis in the mice that were infected with rCD66c bound IAV ( Figure In our search for a receptor for IAV, we chose to follow the experimental path followed by 297 many other research groups to identify new viral receptors (13-20). We conducted similar 298 experiments in detail, which could validate the interaction between viral NA and host CD66c at 299 the outer cell surface, during IAV attachment and entry. The results thus obtained from these 300 experiments provided sufficient evidence that suggested CD66c as the glycoprotein receptor for 301 influenza virus. The validation of a protein receptor for influenza virus from this study provides 302 valuable insights into some unresolved problems of influenza entry. For instance, it was cited in 303 the earlier studies on influenza entry that although sialic acid was required for virus binding, a 304 specific subset of glycoprotein receptors was necessary for effective viral entry (8, 9), which is 305 yet unknown. Therefore, with the results presented here, we suggest that CD66c is at least one, 306 of the possibly many, glycoprotein receptors. Additionally, this study may further lead to the 307 discovery of other glycoprotein receptors or co-receptors playing a role in virus entry besides 308
CD66c. The mechanism of virus entry is poorly understood and different alternative routes 309 were suggested for IAV entry, such as clathrin-mediated endocytosis, non clathrin-mediated, 310 author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/104026 doi: bioRxiv preprint 13 caveolin-mediated endocytosis or macropinocytosis (21-28). We believe, CD66c, as a receptor 311 for the influenza virus will help in elucidating the precise route for virus-entry and pave the 312 way for discovery of other co-receptors and their mechanism. 313
Further, with this finding we noticed that IAV follows an infection pattern that is 314 similar to some other viruses wherein they take advantage of adhesive properties of hosts cell 315 adhesion molecules (CAMs), for their attachment and entry. For example, Coronavirus, Rabies, 316
Reovirus and Rhinovirus, employ the following cell adhesion molecules CEACAM1, NCAM-1, 317 JAM-A, ICAM-1 respectively, as their receptor for cellular entry (13-15). Additionally, viruses 318 often interact and utilize these cell adhesion molecules (CAMs) to foster a contact between 319 infected and uninfected target cells for an effective cell-to-cell spread (29). Carcinoembryonic 320
Cell Adhesion Molecule 6 (CEACAM6/CD66c) as the receptor for IAV opens opportunities for 321 further investigations on cell-to-cell spread for this virus as well. Our result showing prominent 322 NA-CD66c interaction at the site of cell-cell junction compared to the rest of the cellular 323 membrane is a preliminary indication in that direction (Figure 1c) . 324
Apart from cell adhesion other unique attributes of CD66c, such as GPI anchoring, lipid 325 raft association and heavy glycosylation (Sialyl-Lewis X ), make it a very suitable and strong 326 receptor candidate for IAV entry. Influenza binding on the cell surface causes lipid raft 327 mediated virus uptake (10), hence we suggest that this putative receptor CD66c being a 328 component of lipid rafts bears potential to further dissect and solve the enigma of the viral 329 internalization mechanism. In addition to that, Sialyl-Lewis X is reported as the common 330 receptor determinant of a number of influenza viruses of the terrestrial poultry (30). Therefore 331 presence of Sialyl-Lewis X on the CD66c molecules makes the latter a strong glycoprotein 332 receptor candidate for the IAV. More importantly, in human lungs there is abundant expression 333 of CEACAM6 by alveolar and bronchial epithelial cells, where it also demonstrates surfactant 334 association and secretion into lung-lining fluid (31). These features of CD66c with respect to 335 human lungs make this molecule vulnerable to respiratory pathogens like IAV. More 336 author/funder. All rights reserved. No reuse allowed without permission.
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including Haemophilus influenzae and Moraxella catarrhalis (32, 33), CEACAM6 (CD66c) 338 from above results, serves as a receptor for yet another respiratory pathogen -IAV. 339
It is reported that when pathogens interact with the CEACAM receptors, there is 340 significant activation of PI3K signaling during internalization of the pathogen (34). In our 341 previous report, we validated the activation of PI3k/Akt pathways when CEACAM6 (CD66c) 342 interacts with influenza NA (12), here we demonstrate viral internalization upon NA-CD66c 343 interaction at the cell surface. Also, this new finding on CD66c provides support to the 344 viewpoint of a contentious argument made in the past on a role for NA in influenza entry (35, 345 36) . 346
More importantly, viruses frequently exploit chemokine receptors, some CD markers 347 and other membrane glycoproteins of IgSF as their receptors for entry and also for 348 manipulating the host defense mechanism (37). For this reason, a majority of these 349 The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/104026 doi: bioRxiv preprint elements of caution into consideration while designing animal experiments and interpreting 362 data thereof ( Figure S1) . 363 Therefore we argue that immunomodulatory studies carried out earlier in abeyance of 364 any glycoprotein receptor for IAV were rather incomplete and CD66c at the helm of 365 immunomodulation and its interaction with virus during internalization has potential to unfold 366 the precise mechanism of influenza infection, consequent immune response and cell tropism. 367
Lack of any identified glycoprotein receptor during IAV attachment and entry, had greatly 368 limited influenza research discourse in this direction whereas similar questions had been 369 addressed well with other viruses (42). for observation under confocal microscope (A1R; Nikon, Tokyo, Japan). For extracellular 429 staining was two-step process, wherein cells fixed in 4% paraformaldehyde were incubated 430 with primary antibody (anti-CD66c or anti-NA) followed by respective fluorescent secondary 431 antibodies, bypassing the cell permeabilisation step. Primary antibody was used at a dilution of 432 1:100 and secondary antibodies were used at a dilution ratio of 1:1000 in antibody solution. 433
434
Flow cytometric analysis 435
For intracellular Influenza NP staining, viral infected cells were washed with PBS and 436 centrifuged to remove debris. Single cell suspension thus formed was fixed with 4% 437 paraformaldehyde (PFA) in PBS. Fixed cells were then washed twice with PBS containing 3% 438 author/funder. All rights reserved. No reuse allowed without permission.
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